StockNews.com Begins Coverage on OpGen (NASDAQ:OPGN)

StockNews.com started coverage on shares of OpGen (NASDAQ:OPGN) in a research report issued to clients and investors on Sunday. The firm set a “sell” rating on the medical research company’s stock.

OpGen Stock Performance

OpGen stock opened at $0.79 on Friday. The firm has a 50-day moving average price of $1.24 and a 200-day moving average price of $1.89. OpGen has a 12-month low of $0.53 and a 12-month high of $9.90.

OpGen Company Profile

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.